Europe Pharmaceutical Intermediates Market Key Companies and SWOT Analysis by 2028

The pharmaceutical intermediates market in Europe is expected to grow from US$ 7,890.84 million in 2021 to US$ 10,135.51 million by 2028; it is estimated to grow at a CAGR of 3.6% from 2021 to 2028.

The UK, Germany, France, Italy, and Spain are major economies in Europe. Pharmaceutical companies are highly investing in the development of drugs and discovery of new pharmaceutical products. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), pharmaceutical companies in the US conduct more than half of the world's R&D, with the investments totaling ~US$ 75 billion, and they hold intellectual property rights on most of the new pharmaceuticals. Further, a research based pharmaceutical industry is an important asset of the European economy and is one of the top-performing high-technology sectors in region. As per the EFPIA member associations, the research-based pharmaceutical industry in Europe invested around US$ 43,437.88 million (€ 36,500 million) in R&D in 2018. Such high investments in the R&D activities by the pharmaceutical companies are further driving the growth of the pharmaceutical intermediates market

Among all European countries, Spain, Italy, Germany, France, and the UK are most affected due to the increasing number of coronavirus cases and deaths associated with it. As per the Worldometer as of April, 2021, in Spain, Italy, Germany, France, and UK, the number of cases is 3,370,256; 3,779,594; 3,021,064; 5,067,216; and 4,373,343 respectively and number of deaths are also high. Various companies have undergone severe losses in the last quarter of 2019 and have negatively impacted the year 2020. As to control the spread of disease, countries have imposed complete lockdown. The lockdown has resulted in slower economies due to closed trades and business.  The health and wellness market in Europe is observing steady growth due to the outbreak of coronavirus pandemic. Europeans are looking for different and natural ways of staying healthy and enhance their immune system. Lockdown and quarantine measures in Europe has led to a change in consumer buying habits. Some health categories are witnessing short-term decline in growth, while few are having positive effect on the sales of vitamins, dietary supplements, and analgesics with a strong focus on immunity and prevention. So, health supplements that were trending fine before the lockdown scenario have suddenly gained more attention as more consumers are looking for products that can help them in staying healthy. Multivitamins is one of the products that is gaining excellent popularity during pandemic. So, there is increased interest in how vitamins and health supplements can help people with their health and wellness in the coronavirus era. In France, specialist organic food shops have reported sales increases of over 40 percent. Holland & Barrett, the leading health food retailer in the UK, put a cap on supplement purchases due to its rising demand. Online retailer Healthspan reported that at end of March 2020, the sales of vitamin C supplements had tripled in a week. These factors are likely to have positive impact on the market growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the pharmaceutical intermediates market. The Europe pharmaceutical intermediates market is expected to grow at a good CAGR during the forecast period.

 

Europe Pharmaceutical Intermediates Market Segmentation

Europe Pharmaceutical Intermediates Market – By Type

• GMP
• Non GMP

Europe Pharmaceutical Intermediates Market – By Application

• Antibiotics
• Antipyretic analgesics
• Vitamins
• Others

Europe Pharmaceutical Intermediates Market – By Distribution Channel

• Distributor
• Direct Sales

Europe Pharmaceutical Intermediates Market- By Country

• Germany
• France
• Italy
• United Kingdom
• Spain
• Rest of Europe

Europe Pharmaceutical Intermediates Market-Companies Mentioned

• BASF SE
• chiracon GmbH
• Codexis
• Dextra Laboratories Limited
• Dishman Carbogen Amcis Ltd
• Midas Pharma GmbH
• Pfizer Inc.
• Sanofi

Europe Pharmaceutical Intermediates Report Scope